Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Canakinumab |
Synonyms | |
Therapy Description |
Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Canakinumab | Ilaris | ACZ-885 | Ilaris (canakinumab) is a monoclonal antibody against interleukin-1beta, which has anti-inflammatory activity and may decrease tumor progression (PMID: 28855077). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04810611 | Phase I | NIS793 Sabatolimab Canakinumab + Sabatolimab NIS793 + Sabatolimab Canakinumab | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS | Active, not recruiting | USA | ITA | ESP | AUS | 4 |
NCT03447769 | Phase III | Canakinumab | Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None) | Terminated | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT | 33 |
NCT05467800 | Phase II | Canakinumab | Study of Canakinumab in Patients With Myelofibrosis | Recruiting | USA | 0 |
NCT03968419 | Phase II | Canakinumab Pembrolizumab Canakinumab + Pembrolizumab | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) | Terminated | USA | FRA | ESP | DEU | CAN | BEL | 6 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | FRA | ESP | CAN | BEL | 3 |